SuperGen Orathecin rolling NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SuperGen begins submission of the rolling NDA for its refractory pancreatic cancer agent Orathecin Dec. 30. The first module contains the chemistry, manufacturing and controls section. The submission is expected to be completed by the end of the first-quarte